Mylan Inc (NASDAQ:MYL) has been soaring high ever since the announcement of the Actavis acquisition of Forest Laboratory surfaced. On Feb. 18, Actavis Plc (NYSE:ACT) announced that it is taking over Forest laboratories Inc. (NYSE:FRX) for a consideration of $25 billion, which resulted in an upsurge in Forest’s shares. The announcement resulted inMylan Inc (NASDAQ:MYL)’s shares to climb over too fueled by speculations that it too could be acquired soon. However, experts believe that these speculations, whatsoever, are ill-informed and are not supported by facts. Mylan Inc (NASDAQ:MYL) stock opened at $52.40 in last session, and closed at $51.92, while the day range of MYL stock is $51.26-$52.40.The stock showed a positive weekly performance of 12.41%.
Actavis plc Ordinary Shares (NYSE:ACT) has essentially positioned itself more strategically for the current fiscal year is it plans to outdo itself in terms of revenue collection while also delivering sustainable long-term organic growth. The massive growth experienced during the fourth quarter and full year was as a result of increased sales of core products in the US. Products such as Rapaflo and Generess Fe franchises hit double figures in terms of growth for the full year. Actavis plc Ordinary Shares (NYSE:ACT) stock opened at $217.99, in last session and closed at $218.41, by loosed -0.89%.The 52 week range was $82.44-$222.24.Company’s market capitalization is $38.05 million.
Catalyst Pharmaceutical Partners Inc. (CPRX) updated that the Company was present at the 16th Annual BIO CEO & Investor Conference, in New York. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) the stock advanced 11.68% and finished the session at $2.20. Traded with volume of 3.03 million shares in the prior session and the average volume of the stock remained 771,578.00 shares. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) stock gained 3.64% and finished the last session at $2.28.The EPS of the stock remained -0.25.Company’s market capitalization is $123.42 million.
Zacks reaffirmed their neutral rating on shares of Zoetis Inc (NYSE:ZTS) in a report issued on Wednesday, American Banking and Market News reports. They currently have a $31.00 target price on the stock. Zoetis Inc (NYSE:ZTS) stock opened the session at $29.99, and closed the session at $29.61.The 52 week range of the ZTS stock remained $28.77-$35.42 and the day range was $29.53-$30.03.
Leave a Reply